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Early Gag Immunodominance of the HIV-Specific T-Cell Response
during Acute/Early Infection Is Associated with Higher CD8 T-Cell
Antiviral Activity and Correlates with Preservation of the CD4 T-
Cell Compartment
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Horacio Salomon,a María Magdalena Gherardia
Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Universidad de Buenos Aires-CONICET, Buenos Aires, Argentinaa; Fundación Huésped, Buenos Aires,
Argentinab; Hospital J.A. Fernández, Buenos Aires, Argentinac; Department of Virology and Immunology, Southwest National Primate Research Center, Texas Biomedical
Research Institute, San Antonio, Texas, USAd
The important role of the CD8 T-cell response on HIV control is well established. Moreover, the acute phase of infection repre-
sents a proper scenario to delineate the antiviral cellular functions that best correlate with control. Here, multiple functional
aspects (specificity, ex vivo viral inhibitory activity [VIA] and polyfunctionality) of the HIV-specific CD8 T-cell subset arising
early after infection, and their association with disease progression markers, were examined. Blood samples from 44 subjects
recruited within 6 months from infection (primary HIV infection [PHI] group), 16 chronically infected subjects, 11 elite control-
lers (EC), and 10 healthy donors were obtained. Results indicated that, although Nef dominated the anti-HIV response during
acute/early infection, a higher proportion of early anti-Gag T cells correlated with delayed progression. Polyfunctional HIV-spe-
cific CD8 T cells were detected at early time points but did not associate with virus control. Conversely, higher CD4 T-cell set
points were observed in PHI subjects with higher HIV-specific CD8 T-cell VIA at baseline. Importantly, VIA levels correlated
with the magnitude of the anti-Gag cellular response. The advantage of Gag-specific cells may result from their enhanced ability
to mediate lysis of infected cells (evidenced by a higher capacity to degranulate and to mediate VIA) and to simultaneously pro-
duce IFN-. Finally, Gag immunodominance was associated with elevated plasma levels of interleukin 2 (IL-2) and macrophage
inflammatory protein 1 (MIP-1). All together, this study underscores the importance of CD8 T-cell specificity in the im-
proved control of disease progression, which was related to the capacity of Gag-specific cells to mediate both lytic and nonlytic
antiviral mechanisms at early time points postinfection.
Human immunodeficiency virus (HIV) still represents a majorpublic health concern. Although the instauration of highly
active antiretroviral treatment (HAART) had a tremendous im-
pact on the epidemic dynamics, the development of an effective
prophylactic vaccine is still a main objective in the HIV-related
research field. As HIV is highly diverse among different isolates,
evolves continuously under selective pressure, infects immune
cells, and encodes proteins with the capacity to modulate immune
cell functions, it imposes definite challenges that should be over-
come in the race of getting a successful vaccine. However, the
description of (i) infected subjects able to control HIV replication
over long periods of time to very low levels without therapy
(known as long-term nonprogressors [LTNP] and elite control-
lers [EC]); (ii) uninfected subjects who, despite being highly ex-
posed to the virus, remain seronegative (exposed seronegatives
[ESN]); and (iii) the results from the Thai vaccine trial RV-144,
which showed 30% efficacy (1), suggests that the objective is
reachable. In this line, much of the research work conducted over
the past few years was aimed to define the immune correlates of
protection, i.e., desirable characteristics that the vaccine-elicited
immune response should have in order to contain viral challenge.
Within this field, special emphasis has been focused on the HIV-
specific CD8 cytotoxic T lymphocytes (CTLs), which are
thought to play a key role in reducing viral replication (2, 3).
The first evidence that specific CD8 T cells were involved in
the control of viral replication was reported in studies conducted
in humans and nonhuman primates during the acute phase of
infection. After infection, emergence of specific CD8 T cells cor-
relates with the decline of peak viremia toward set point establish-
ment, which varies from person to person and is a strong predictor
of disease progression (4). Also, CTL escape mutants have been
described (5, 6), and superior viral control has been attributed to
specific human leukocyte antigen (HLA) class I alleles (7, 8).
Moreover, recent proof-of-concept vaccine studies in nonhuman
primates indicate that vaccine-elicited CD8 T-cell responses are
associated with partial protection from infection and with en-
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hanced control of breakthrough infections (9, 10), reinforcing the
notion that specific CD8 T cells exert a pivotal role in viral con-
trol. In-depth analyses of this cellular population, performed in
different cohorts and models, suggest that specificity, quality, and
phenotype are all determinants of CD8 T-cell ability to mediate
control: specificity in terms of viral targets (11–15); quality in
terms of avidity and capacity to mediate viral suppression, prolif-
erate, and secrete a broad spectrum of chemokines and cytokines
(16–20); and phenotype in terms of memory sub-subsets and ex-
pression of exhaustion markers (21–23).
Cell samples obtained during the acute/early HIV infection
constitute invaluable tools to understand the functional features
of the HIV-specific CD8 T cells that best correlate with the low-
er-set-point/protection-from-progression axis and future con-
trol. For sure, these approaches will help dissect the correlates of
protection needed to develop an effective prophylactic vaccine.
Besides, vaccine-elicited highly suppressive specific CD8 T cells
would help constrain viral replication to very low levels in break-
through infections occurring in vaccinees, which in turn would
contribute to a slower progression of the newly infected person as
well as lower transmission risk (24).
We have previously worked with acute phase samples in order
to evaluate Nef-specific cross-clade T-cell reactivity in samples
from subtype B- and BF-infected subjects (25). In that study, dif-
ferences in the CD8 T-cell population functional profile were
observed among subjects, finding an association between CD8
T-cell polyfunctionality and viral control. In the manuscript, we
sought to analyze multiple aspects of the HIV-specific CD8 T-
cell compartment (specificity, ex vivo viral inhibitory capacity, and
polyfunctionality) arising early after infection in a larger cohort,
in comparison with the response found in viremic chronics and
elite controllers, with the aim to delineate CD8 T-cell features
that best associate with disease control and that would contribute
to rational vaccine design. Briefly, it was found that a higher rela-
tive proportion of Gag- than Nef-specific cells, even very early
after infection, strongly associated with delayed progression dur-
ing the first year postinfection, in consonance with Gag immu-
nodominance in EC and chronically infected “viremic control-
lers.” The advantage of Gag-specific cells may result from their
enhanced ability to mediate lysis of infected cells (evidenced by
higher capacity to degranulate and to mediate viral inhibition ac-
tivity in vitro) and simultaneously produce IFN-. Also, a direct
association between the level of Gag immunodominance and
plasma levels of interleukin 2 (IL-2) and macrophage inflamma-
tory protein 1 (MIP-1) was observed. These data underscore
the importance of considering both cell specificity and quality in
the design and evaluation of HIV vaccine candidates.
MATERIALS AND METHODS
Study subjects. A total of 81 subjects participated in this study: 10 healthy
HIV-seronegative donors (HD) and 71 HIV-infected patients, of whom
44 were enrolled during acute/early primary HIV infection (PHI), 16 were
chronically infected patients (chronics), and 11 were elite controllers (EC)
(Table 1; see also Table S1 in the supplemental material). PHI subjects
were enrolled by the Grupo Argentino de Seroconversión Study Group
under the following inclusion criteria (26): (i) detection of HIV RNA or
p24 antigen with a simultaneous negative or indeterminate Western blot
assay or (ii) positive Western blot assay with a negative test within the
previous 6 months. Chronically infected patients were defined as subjects
with established HIV infection older than 3 years, with detectable viral
load (VL; 50 HIV RNA copies/ml plasma), and who are HAART naive,
while EC were defined as subjects infected for more than 5 years with
undetectable VL (50 HIV RNA copies/ml plasma) who are HAART
naïve and have no record of opportunistic infections and/or AIDS-related
diseases. The study was reviewed and approved by two institutional review
boards (IRB): Comité de Ética Humana, Facultad de Medicina, Universi-
dad de Buenos Aires, and Comité de Bioética, Fundación Huésped (Bue-
nos Aires, Argentina). Both HIV-infected participants and healthy donors
provided written informed consent accepting to participate in this study.
Samples. Blood samples were collected from study participants at en-
rollment and centrifuged to separate plasma, which was stored at 80°C
until use. Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Hypaque density gradient centrifugation (Amersham, Sweden)
and cryopreserved for subsequent functional assays. For PHI subjects,
additional samples were obtained at 3, 6, 9, and 12 months postinfection.
In the case of chronic, EC, and PHI subjects, plasma VL (branched-DNA,
Versant HIV-1 RNA 3.0 assay; Siemens Healthcare) and CD4 T-cell
count (flow cytometry double platform, BD FACSCanto; BD Biosciences)
were determined.
HLA typing. Human leukocyte antigen (HLA) class I typing was per-
formed using an in-house protocol consisting of PCR amplification, nu-
cleotide sequencing with nested primers, and Web-based sequence inter-
pretation (R. S. Coloccini and D. C. Monaco, unpublished data). HLA-A
TABLE 1 Summary of clinical data corresponding to enrolled HIV subjects per study group

















All (n 	 44) 98,684 (13,161–477,708) 4.6  1.2 4.5  0.8 525 (320–678) 526 (357–656)
PHI  350 (n 	 23) 32,473 (9,532–116,129) 4.2  1.2 4.3  0.6 633 (587–786) 586 (491–680)
PHI  350 (n 	 18) 269,532 (101,394–500,000) 5.2  1.0 5.0  0.8 292 (244–375) 281 (234–327)
Chronic (n 	 16) 16,682 (2,136–41,677) 4.1  0.7 455 (164–577)
Chronic excluding viremic controllers (n 	 12) 22,267 (13,296–44,758) 4.4  0.5 287 (140–544)
EC (n 	 11) 50 1,7 595 (562–817)
a Versant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits are 50 and 500,000 RNA copies/ml, respectively (1.7 and 5.7log10).
b Flow cytometry double platform, FACSCanto, BD Biosciences.
c For PHI subjects, data correspond to baseline samples. For chronic and elite controller subjects, data correspond to samples obtained at enrollment.
d Set points were not calculated for subjects that initiated HAART during the first year postinfection.
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exons 2 and 3 were amplified in one amplicon. HLA-B exons 2 and 3 were
amplified separately. The amplification of exon 3 was performed by
heminested PCR, using 2 different reverse primers. Similarly, HLA-C ex-
ons 2 and 3 were amplified separately using a heminested PCR strategy (2
different forward primers) in the case of exon 2. Amplicons were directly
sequenced using the BigDye Terminator sequencing kit (Amersham, Swe-
den) on an automatic sequencer (Applied Biosystems DNA Sequencer
3100). Nucleotide sequences were analyzed and manually adjusted using
Sequencher 4.10.1 software (Gene Codes Co.). Sequence interpretation
was performed using the NCBI SBT Interpretation software, available
online (http://www.ncbi.nlm.nih.gov/gv/mhc/sbt.cgi?cmd	main).
Peptides. Potential T-cell epitope (PTE) peptide panels correspond-
ing to Nef, Gag, and Env proteins and the cytomegalovirus (CMV), Ep-
stein-Barr virus, and influenza virus (CEF) peptide pool were obtained
from the NIH AIDS Reagent Program (27, 28). Lyophilized peptides were
dissolved in dimethyl sulfoxide (DMSO) at 40 g/l and stored at 20°C.
The PTE peptides are 15 amino acids (aa) in length and contain nat-
urally occurring 9-aa sequences that are potential T-cell determinants
embedded in the sequences of circulating HIV-1 strains worldwide. Here,
the PTE peptides were grouped in 9 pools: 1
 Nef (n 	 127 peptides), 3

Gag (corresponding to p17 [n 	 97], p24 [n 	 128], and p2p7p1p6 [de-
noted as RG; n 	 95]), and 5
 Env (Gp120A1 [n 	 73, spans HXB2 Env
aa positions 1 to 154], Gp120A2 [n 	 73, aa 157 to 284], Gp120B [n 	 105,
aa 287 to 511], Gp41A [n 	 114, aa 513 to 689], Gp41B [n 	 115, aa 689
to 842]).
ELISPOT assay. Gamma interferon (IFN-)-secreting cells were eval-
uated using enzyme-linked immunospot (ELISPOT) assays as described
previously (25). Briefly, cryopreserved PBMCs were thawed in complete
RPMI medium (RPMIc; RPMI 1640 [Gibco BRL], 10% fetal bovine se-
rum [FBS; Gibco BRL], 2 mM L-glutamine [Gibco BRL], 100 U/ml peni-
cillin [Gibco BRL], 100 g/ml streptomycin [Gibco BRL], 10 mM HEPES
[Gibco BRL]) supplemented with 50 U/ml DNase I (Benzonase nuclease;
Sigma-Aldrich) and then rested overnight in DNase-free medium at a
density of 106 cells/ml. Cell viability was checked by trypan blue exclusion
after thawing and overnight rest. Rested PBMCs with 95% viability were
plated on sterile 96-well plates (MultiScreen IP plates; Millipore), previ-
ously coated with mouse anti-human IFN- monoclonal antibody (BD
Biosciences) at 105 cells/well, and peptide pools were added at a final
concentration of 2 g/ml of each peptide. Final DMSO concentration was
always lower than 0.7%. Negative (peptide-free medium plus 0.5%
DMSO), CEF peptide pool (2 g/ml of each peptide), and phorbol my-
ristate acetate (PMA)-ionomycin (5 ng/ml PMA plus 500 ng/ml ionomy-
cin; Sigma-Aldrich) controls were assayed for each patient. Plates were
developed using biotinylated anti-human IFN- monoclonal antibody,
streptavidin-peroxidase complex, and the 3-amino-9-ethylcarbazole
(AEC) substrate reagent set (BD Biosciences). Plates were scanned on an
ImmunoSpot reader (Cellular Technology Ltd.). Specific spot count and
spot size were calculated using the ImmunoSpot software. Results were
expressed as spot-forming units (SFU)/106 PBMCs after subtraction of
the negative-control values. Thresholds for positive responses for the test
wells were defined as at least 50 SFU/106 PBMCs or as mean SFU greater
than three times the mean SFU of the negative-control wells, whichever
was higher.
Virus inhibitory activity. Ex vivo CD8 T-cell capacity to inhibit viral
replication in primary autologous CD4 T cells was assayed following the
protocol published by Sáez-Cirión et al. (29) with minor modifications:
bulk CD4 T cells were isolated from thawed and overnight rested
PBMCs by positive selection with anti-CD4 antibody-coated magnetic
beads (BD Biosciences) and kept for 3 days in RPMIc supplemented with
1 g/ml phytohemagglutinin (PHA; Sigma-Aldrich). CD4 T-cell-de-
pleted PBMCs were then subjected to CD8 T-cell-positive selection with
anti-CD8 antibody-coated magnetic beads (BD Biosciences). Sorted
CD8 cells were cultured for 3 days in RPMIc without PHA.
At day three postisolation, CD4 and CD8 cells were washed,
counted, and plated in U-bottom 96-well plates at a 1:1 ratio. Cells were
then infected with X4-tropic (HIVLAI) or R5-tropic (HIVBAL) HIV-1 lab-
oratory strains at a multiplicity of infection (MOI) of 0.001. In order to
improve infection efficiency, plates were first centrifuged at 1,200 
 g for
1 h at 22°C (spinoculation), and then adsorption was let to proceed for an
extra hour at 37°C in a humidified CO2 incubator. After infection, cells
were washed twice and resuspended in RPMIc medium containing IL-2 at
a final concentration of 10 U/ml. At day 3 postinfection, the cocultures
were fed by replacing one-half of the culture supernatant with fresh me-
dium. At day 7 postinfection, supernatants were removed and p24 antigen
was quantified by enzyme-linked immunosorbent assay (ELISA; Virono-
stika HIV-1 antigen kit; bioMérieux, France). Uninfected cocultures were
included as negative controls, and infected CD4 T cells without added
effectors (CD8 T cells) served as 100% infectivity controls. All condi-
tions were assayed in triplicate. CD8 T-cell anti-HIV suppressive capac-
ity was calculated as the log10 of the percentage of p24 antigen lost when
CD8 T cells were present in the culture.
Intracellular cytokine staining (ICS). Production of cytokines and
degranulation of HIV-specific cells were measured upon stimulation by
flow cytometry following the protocol published before (25) with the
following modification: thawed and overnight rested PBMCs were dis-
pensed in U-bottom 96-well plates (5 
 105 cells/well) in duplicate wells.
Cell viability was checked before and after overnight rest by trypan blue
exclusion (only samples with 95% viability after the overnight rest were
used for the assays). Costimulatory antibodies (anti-CD28 and anti-
CD49d antibodies, 1 g/ml; BD Biosciences), monensin (Golgistop, 0.7
l/ml; BD Biosciences), brefeldin A (10 g/ml; BD Biosciences), and the
corresponding peptide pool (2 g/ml) were added. An unstimulated
(peptide-free medium plus 0.5% DMSO and costimulatory antibodies)
and two positive controls (2 g/ml CEF peptide pool and PMA-ionomy-
cin) were included in each assay. A mixture of anti-CD107A-fluorescein
isothiocyanate (FITC) and anti-CD107B-FITC antibodies (BD Biosci-
ences) was added to one of the replicates. Cells were incubated for 6 h at
37°C, washed, and stained for 30 min at 4°C with LIVE/DEAD Fixable
NEAR-IR (Invitrogen), in order to exclude dead cells, and with anti-CD3-
PerCP and anti-CD8-APC surface antibodies (BD Biosciences). Then,
cells were permeabilized and fixed using the Cytofix/Cytoperm kit (BD
Biosciences). After the permeabilization/fixation step, one of the repli-
cates was stained using anti-IL-2–phycoerythrin (PE), anti-tumor necro-
sis factor alpha (TNF-)-FITC, and anti-IFN-–PECy7 antibodies (BD
Biosciences), while replicates already containing the anti-CD107A/B mix
were stained with anti-IL-2–PE and anti-IFN-–PECy7. Cells were then
washed and stored until data acquisition in a 2-laser, 6-color BD
FACSCanto flow cytometer. Data acquisition and analysis were per-
formed using the BD FACSDiva software. Instrument settings and fluo-
rescence compensation were performed for each day of testing using un-
stained and single-stained samples. Isotype controls (consisting of
stimulated cells stained with conjugated antibodies to surface molecules
and isotype controls corresponding to intracellular markers) were per-
formed for each patient in order to accurately set negative populations.
First, a plot of forward scatter area (FSC-A) versus height (FSC-H) was
constructed to remove doublets. Then, gating was performed on small
lymphocytes in a plot of FSC versus side scatter (SSC). At least 80,000
events were acquired in the lymphocyte gate. Dead cells were then ex-
cluded on the bases of LIVE/DEAD fluorescence. Subsequently, CD3
CD8 cells were gated in a CD3-versus-CD8 dot plot. Following identifi-
cation of these cells, a gate was made for each function studied (see Fig.
5A). To study 2-function and 3-function positive populations, “derived
gate tools” available in the FACSDiva software was used. For this purpose,
intersections of two and three gates were created, respectively. Once the
percentages of events were determined for each derived gate, the value of
triple-positive events was subtracted from those of double-positive events
and, in turn, double- and triple-positive events were subtracted from the
total events positive for a given function to calculate monofunctional cells.
Samples with a nonspecific background higher than 0.05% for any func-
tion were retested using a new vial of frozen cells. Data presented corre-
CTL Specificity and Function in HIV Acute Infection
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spond to background-subtracted results using the CD28/CD49d-only
stimulation. This was performed on a cytokine-subset-by-cytokine-sub-
set basis, i.e., subtracting the result from the CD28/CD49d-only condition
for a given cytokine subset to the same subset of a peptide-stimulated
condition. Two standard deviations (SDs) above background was set as
the threshold for determining positive responses. Values below this
threshold were set at 0.
For certain cell functions, relative mean fluorescence intensity (rMFI)
was calculated as the ratio between MFI corresponding to specific versus
total CD8 T cells for a given channel.
Quantification of plasma soluble factors. Simultaneous determina-
tion of the following 39 cytokines and chemokines was performed in
plasma samples from a subset of 28 PHI subjects (at baseline time point
only) using Luminex technology (MILLIPLEX MAP Human Cytokine/
Chemokine; Millipore): epidermal growth factor (EGF), eotaxin, FGF-2,
Flt-3 ligand, fractalkine, granulocyte colony-stimulating factor (G-CSF),
granulocyte-macrophage colony-stimulating factor (GM-CSF), GRO,
IFN-2, IFN-, IL-1, IL-1, IL-1r, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7,
IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10,
monocyte chemoattractant protein 1 (MCP-1), MCP-3, MDC (CCL22),
MIP-1, MIP-1, sCD40L, sIL-2R, transforming growth factor alpha
(TGF-), TNF-, TNF-, VEGF. Samples were processed and analyzed as
described by Giavedoni (30).
Data analysis. For PHI subjects, viral and CD4 set points were calcu-
lated as the geometric mean of the determinations obtained between 6 and
12 months after the presumed date of infection. Set points were not cal-
culated for those subjects who started HAART during the first 12 months
from infection or if no stable set point was reached during that period.
Statistical analyses were performed using GraphPad Prism 5 (Graph-
Pad Software). All data except log10 VL and breadth of response were
analyzed using nonparametric statistics. Two-tailed Wilcoxon and Mann-
Whitney tests were used to compare intra- and intergroup variables, re-
spectively. Correlations were determined using Spearman’s rank test. All
tests were considered significant if the P value obtained was less than 0.05.
For correlations between plasma cytokine levels and immune parameters,
P values were adjusted for multiple comparisons using a false discovery
rate (FDR) procedure, according to the Benjamini & Hochberg method,
with R Project software version 2.10.0. Adjusted P values were considered
significant when less than 0.1.
RESULTS
Study subject descriptions. Three groups of HIV-infected sub-
jects were enrolled as follows in order to attempt to dissect im-
mune mechanisms associated with control over disease progres-
sion during acute/early HIV infection: 44 subjects recruited
during HIV seroconversion and/or within 6 months from pre-
sumed date of infection (PHI group), 16 chronically infected sub-
jects (chronics), and 11 subjects defined as elite controllers (EC)
according to the criteria defined in Materials and Methods. De-
tailed descriptions of the HIV-infected participants are shown in
Table S1 in the supplemental material. Baseline samples for most
PHI subjects were obtained during Fiebig stages V and VI (31).
Within this group, median baseline VL was 98,684 RNA copies/ml
(25 to 75% interquartile range [IQ], 13,161 to 477,708 copies/ml).
As expected, it was statistically higher than chronics’ VL (median,
16,682 RNA copies/ml [IQ, 2,136 to 41,677], P 	 0.012]) and, of
course, EC’s VL (Table 1 and Fig. 1). Median baseline CD4 T-cell
count for PHI (525 cells/l [IQ, 320 to 678]) did not differ signif-
icantly from the median CD4 T-cell count of chronics (455
cells/l [IQ, 164 to 577]) or EC (595 cells/l [IQ, 562 to 817]), but
a statistically significant difference was found between chronics
and EC (P 	 0.018) (Fig. 1). For those PHI subjects who remained
HAART naive during the first year postinfection, viral and CD4
T-cell set points were calculated (Table 1 and Fig. 1; see Table S1 in
the supplemental material). These parameters did not differ sig-
nificantly from chronics’ VL and CD4 T-cell count. Of note, the
group of chronically infected subjects enrolled for this work is very
heterogeneous and includes four subjects that could be classified
as what some authors refer to as viremic controllers, i.e., individ-
uals able to spontaneously control viral load below 2,000 RNA
copies/ml (32) (C03, C05, C07, C08; Fig. 1; see also Table S1 in the
supplemental material). After removing these subjects from the
analysis, median VL for the chronic group was 22,267 RNA cop-
ies/ml (IQ, 13,296 to 44,758), and median CD4 T-cell count was
287 cells/l (IQ, 140 to 544) (Table 1).
PHI subjects were further divided into two subgroups whether
their CD4 T-cell count dropped below 350 cells/l at any time
during the first year postinfection or not (PHI  350 and PHI 
350). By doing this, we were aimed to differentiate subjects with
more rapid or aggressive progression of early infection (PHI 
350 group) and to investigate the association of this pattern with
the immune parameters analyzed in this work. The 350-cells/l
endpoint was chosen based on the national and international rec-













































FIG 1 Viral load (A) and CD4 T-cell count (B) of enrolled HIV subjects per study group. For PHI subjects, values corresponding to both baseline and set point
are shown. Also, PHI subjects are shown as a whole group (PHI) and split into PHI  350 and PHI  350 subgroups whether their CD4 T-cell count dropped
below 350 cells/l at any time during the first year postinfection or not. Within the chronic group, black dots correspond to viremic controllers (see Table S1 in
the supplemental material and the text). Horizontal lines stand for median values. P values were calculated using Mann-Whitney test. VEGF, vascular endothelial
growth factor; MDC, macrophage-derived chemokine; GRO, growth-related protein. Asterisks denote different P values: *, P  0.05; ***, P  0.005.
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when most of these individuals were already enrolled (26). The
PHI  350 and PHI  350 groups differed significantly in both
baseline and set point VLs and CD4 T-cell counts (Table 1, Fig. 1).
Distribution of HLA alleles in enrolled subjects as a whole re-
flected the frequency distribution described for Argentina’s urban
population (www.allelefrequencies.net). To exclude the possibil-
ity of enrichment of particular HLA alleles associated with faster
(A01, A68, B35) or slower (B27, B51, B57) HIV disease course, the
frequency of these alleles was studied per study group. No signif-
icant differences in the frequency of A01, A68, or B35 alleles were
found among groups, even for the EC group, where these alleles
were found in 4 out of 11 subjects (36% versus 41% of chronics
and 47% of PHI subjects) (see Table S1 in the supplemental ma-
terial). On the other hand, “protective alleles” B27, B51, or B57
were present in one subject from the PHI  350 group, three
subjects from the PHI  350 group, one PHI subject with unde-
termined progression status, three chronically infected subject,
and only three EC. So, the different disease progression rates
among groups cannot be explained merely by differences in the
genetic background, at least based on the HLA-I locus level.
Screening of HIV-specific T-cell responses by ELISPOT re-
vealed differences between progressive and nonprogressive in-
fection regarding magnitude, preferred targets of specific re-
sponse, and quality. To evaluate how the central targets,
magnitude, and quality (in terms of breadth and capacity to re-
spond upon stimulation) of the HIV-specific cellular immune re-
sponse during the acute/early phase of infection impact early
disease progression, HIV-specific IFN--secreting cells were
screened by ELISPOT in PHI subjects using samples obtained at
baseline (defined as the first sample obtained after enrollment
according to the criteria defined in Materials and Methods). PTE
peptide pools spanning the viral proteins Nef (1 pool), Gag (3
pools), and Env (5 pools) were used as stimuli. Also, these HIV-
specific immune responses were screened in chronics and EC for
comparison purposes.
(i) Magnitude and targets of HIV-specific cellular immune
response in PHI, chronics, and EC. The median magnitude of the
specific immune response (expressed as the number of SFU/106
PBMCs) was higher in EC for all three antigens evaluated than in
chronic and PHI subjects. This difference was particularly impor-
tant in terms of Gag antigen: EC showed a 5-fold-higher median
Gag-specific magnitude than chronic and PHI subjects (median
Gag-specific magnitude 	 3,570, 692, and 145 SFU/106 PBMCs
for EC, chronics, and PHI subjects, respectively [EC versus chron-
ics, P 	 0.025; EC versus PHI subjects, P 	 0.0003]; Fig. 2A).
Intragroup analysis showed that anti-Gag magnitude was signifi-
cantly higher (6-fold) in EC than Nef (median, 656 SFU/106
PBMCs; P 	 0.005) and Env (median, 590 SFU/106 PBMCs; P 	
0.007), while the anti-Nef magnitude in the PHI group (median,
308 SFU/106 PBMCs) tended to be higher than anti-Gag magni-
tude (median, 145 SFU/106 PBMCs; P 	 0.06). Also in the PHI
group, both anti-Nef and anti-Gag magnitude were significantly
higher than anti-Env magnitude (median, 35 SFU/106 PBMCs;
P 	 0.015 and P 	 0.014, respectively) (Fig. 2A).
The relative contribution of each antigen to the total response,
i.e., the proportion of cells specific for each protein relative to the
total anti-HIV response, is an important factor to be taken into
account when evaluating the association of HIV-specific immune
response with viral control (11). Thus, the proportion of specific
cells against each HIV antigen in relation to the total response
(sum of the T-cell responses against the individual antigens) was
analyzed (Fig. 2B). Again, the contribution of the different targets
differed among the different study groups: PHI subjects showed a
statistically higher proportion of Nef-specific cells (median, 55%)
than chronics (median, 17%; P 	 0.005) and EC (median, 20%;
P 	 0.007) and lower proportion of anti-Gag-specific cells (PHI,
32% versus EC, 64% [P 	 0.004]; PHI versus chronics, 64% [P 
0.05]). In the same line, intragroup analysis revealed that anti-Gag
response (median, 64%) clearly predominated over Nef (20%)-
and Env (7.4%)-specific cells in EC (Gag versus Nef, P 	 0.005;
Gag versus Env, P 	 0.007), whereas anti-Nef cells predominated
in PHI (median, 55%) over Gag (32%, P 	 0.001) and over Env
(6%, P  0.001). The chronic group showed the same immu-
nodominance pattern (Gag  Nef  Env) than EC, although the
response dispersion among chronics was much higher, which re-
flects the heterogeneity of this group. When analyzing separately
the chronic subjects referred to as viremic controllers, it could be
observed that the median percentage of Gag immunodominance
in this chronic subgroup was 86%, considerably higher than that
of regular chronics (43%).
When a similar analysis was performed within PHI subgroups,
it could be observed that the scenario is clearly different between
PHI  350 and PHI  350 groups: while no statistically significant
difference could be observed between anti-Nef and anti-Gag mag-
nitude or proportion of total response in the PHI  350 group,
anti-Nef cells clearly dominated the anti-HIV response in the
PHI  350 group (median magnitude, 500 SFU/106 PBMCs; me-
dian proportion of total response, 62%) over Gag and Env both in
terms of magnitude (80 SFU/106 PBMCs [P 	 0.0125] and 77
SFU/106 PBMCs [P 	 0.001], respectively) and proportion (32%
[P 	 0.01] and 7% [P 	 0.003], respectively) (Fig. 2A and B).
Given the significant role that anti-Nef and anti-Gag responses
seem to play in defining the different rates of progression among
groups, the contribution of anti-Nef and anti-Gag T-cell re-
sponses (relative to the sum of the magnitude obtained for both
antigens) was analyzed per individuals included in the different
groups (Fig. 2C). Anti-Gag responses clearly dominated over Nef
in all EC (P 	 0.002). On the opposite sense, anti-Nef responses
dominated the anti-HIV response in the group of rapid progres-
sors, PHI  350 (P 	 0.008). In chronics and the PHI  350
group, an intermediate situation was observed: Gag dominated
over Nef only in a subset of individuals, while the rest showed
either Nef immunodominance or a balanced situation between
both antigens. Among the chronic group, those with clear Gag
immunodominance included those previously referred to as
“viremic controllers” (C03, C05, C07, and C08).
It must be noted that the immunodominance hierarchy ob-
tained with baseline samples was maintained when using samples
obtained 1 year postinfection (data not shown), thus similar ten-
dencies were observed when analysis was performed with the 12-
month samples.
Then, a more detailed analysis of the Gag polyprotein subunits
targeted by cells from the recruited individuals was performed. In
all groups (chronic, EC, and PHI subjects as a whole), the immu-
nodominance pattern (according to medians) was as follows:
p24  p17  RG (Fig. 2D). Only in EC, the anti-Gag response was
focused into p24 protein in a significantly higher proportion over
both p17 and RG (P 	 0.047 and 0.032, respectively). In chronics
and PHI subjects, the proportion of anti-p24 response was signif-
icantly higher than the anti-RG response (P 	 0.0012 and P 	
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0.0021, respectively) and also tended to be higher than the anti-
p17 response, although the difference was not statistically signifi-
cant in either group. When PHI subjects were split into PHI  350
and PHI  350, it was observed that the PHI  350 group main-
tained the immunodominance pattern observed before, whereas a
shift to p17  p24  RG was observed in the PHI  350 group.
(ii) Quality (in terms of breadth and intensity of IFN- pro-
duction upon stimulation) of the HIV-specific cell immune re-
sponse in PHI, chronic, and EC groups. Afterward, the breadth of
the response was calculated for each individual as the number of
peptide pools recognized (out of the 9 pools used to screen HIV-
specific response) (Fig. 2E). This analysis revealed that EC were
able to recognize a higher number of pools than chronics and PHI
(P 	 0.05 and 0.002, respectively). Even more, EC were able to
recognize more Gag-specific pools (n 	 3 pools) than chronics
and the PHI group (not shown). No statistically significant differ-
ence was observed between the PHI  350 and PHI  350 groups.
Finally, the mean spot size obtained for both CEF and HIV
peptide pools was recorded as the measure of the amount of IFN-
produced by the individual specific T cells (which in turn corre-
lated with the T-cell functional avidity) (33) (Fig. 2F). No intra-
subject difference was observed among the different HIV-specific
pools (Nef, Gag, and Env) (data not shown). Hence, for the pur-
pose of this analysis, the mean spot size for all HIV antigens was
averaged, taking into account only those pools for which a positive
response was obtained in the ELISPOT assay on a subject-by-
subject basis. Regarding the control CEF-specific spots, PHI sub-
jects showed the smallest size being statistically different from EC
(EC CEF-specific spots were 1.5 times larger than in the PHI
group, P 	 0.029), which in turn showed the largest CEF-specific
spots, even slightly larger than healthy donors (P  0.05). This
difference in the PHI group was driven by PHI  350 subjects who
even differed substantially from their countergroup, PHI  350
(spots from the PHI  350 group doubled, on average, those of
the PHI  350 group). A similar scenario was observed for HIV-
specific spots but, in this case, differences among groups were
stronger. EC showed significantly larger spots than the chronic
and PHI groups (1.5
 [P 	 0.004] and 1.7 
 [P 	 0.002], respec-
tively). Within the PHI group, a significant difference could be
observed between the PHI  350 and PHI  350 groups, showing
the former group had larger HIV-specific spots (1.87
, P 	
0.022). Interestingly, when CEF- versus HIV-specific spot size was
analyzed intragroup, the HIV spots were smaller than CEF spots.
In fact, the spot size difference between the two antigens reached
statistical significance in chronics (P 	 0.036), PHI as a whole (P 	
0.011), and the PHI  350 group (P 	 0.018). Although the trend
was also observed in EC and the PHI  350 group, the breach
between both antigens was less important, especially in EC.
(iii) In acute/early infected subjects (PHI group), baseline
relative immunodominance of anti-Gag cellular response cor-
relates with both baseline and set point CD4 T-cell counts. In
Fig. 2C, it can be observed that the EC and PHI  350 group
(opposed groups in terms of disease progression) showed exactly
opposite immunodominance patterns regarding Nef and Gag
proteins. Based on this observation, it was hypothesized that in the
much heterogenous chronic and PHI  350 groups, Gag immu-
nodominance correlates with slower disease progression. To test
this hypothesis, correlation analyses were performed between the
percentages of anti-Gag responses and clinical data of enrolled
subjects. It was found that baseline relative Gag immunodomi-
FIG 2 ELISPOT screening of HIV-specific T-cell response magnitude, immunodominant targets, breadth, and functionality in primary HIV infection (PHI,
baseline samples), chronic, and elite controller (EC) groups. (A) Magnitude of total anti-Nef, anti-Gag, and anti-Env T-cell responses, expressed as SFU/106
PBMC. (B) Contribution of each antigen relative to the total HIV response expressed as the percentage out of the total sum of the specific response (sum of the
magnitude obtained for all Nef, Gag, and Env antigens). (C) Contribution of anti-Nef and anti-Gag responses (relative to the sum of the magnitude obtained for
both antigens) on a subject-by-subject basis (each represented by a line) in chronic, EC, and PHI groups. “Viremic chronics” are denoted in the corresponding
panel with dashed lines. (D) Gag subunits targeted per study group, expressed as percentage out of the total anti-Gag response. RG 	 p2p7p1p6. (E) Breadth of
the response expressed as the number of peptide pools recognized out of the 9 HIV pools assayed. (F) Mean spot size obtained for both CEF and HIV peptide
pools. HIV mean spot sizes represent the average mean spot sizes out of all Nef, Gag, and Env pools for which a positive response was obtained in the ELISPOT
assay on a subject-by-subject basis. All data presented in the figure for PHI subjects correspond to baseline samples. PHI  350 and PHI  350 stand for
subgroups within the PHI group in which subjects were segregated according to whether their CD4 T-cell count dropped below 350 cells/l at any time during
the first year of infection or not. Horizontal lines within boxes represent the median values. Intra- and intergroup differences were analyzed using Wilcoxon and
Mann-Whitney tests, respectively. Asterisks denote different P values: *, P  0.05; **, P  0.01; ***, P  0.005.



































































FIG 3 Correlation between the relative baseline immunodominance of anti-Gag response and CD4 T-cell counts. (A) Baseline CD4 T-cell count versus
baseline percentage of anti-Gag response in PHI subjects. (B) Set point CD4 T-cell count versus baseline percentage of anti-Gag response in PHI subjects. (C)
CD4 T-cell count versus percentage of anti-Gag response in chronics. In panels A and B, black and white dots denote PHI  350 and PHI  350 subjects,
respectively. In panel C, black dots correspond to viremic controllers within the chronic group. All r and P values correspond to Spearman’s test.
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nance in PHI subjects (baseline Gag%) significantly correlated
with baseline CD4 T-cell counts (Spearman’s r 	 0.3836, P 	
0.01; Fig. 3A). More interestingly, baseline Gag% also significantly
correlated with set point CD4 T-cell count (Spearman’s r 	
0.3630, P 	 0.04; Fig. 3B), indicating that Gag immunodomi-
nance is an important factor shaping disease progression in terms
of CD4 T-cell loss. A similar association between these parame-
ters was found within the chronic group, although the trend did
not reach statistical significance, likely due to the smaller sample
size (Spearman’s r 	 0.4842, P 	 0.09; Fig. 3C).
All together, data collected so far demonstrate that although
Nef dominates the anti-HIV response in acute/early infection, a
higher proportion of early T-cell responses targeting preferentially
Gag (in particular p24) and larger spot size (indicative of im-
proved capacity to secrete IFN- and higher avidity) were associ-
ated with delayed progression during the first year of infection.
Also, these same factors were observed in chronically infected elite
controllers (EC), indicating that these T-cell features may play an
important role in protection from progression. In particular, early
Gag immunodominance correlated with higher CD4 T-cell
counts, both at baseline and set point, further denoting it repre-
sents a key immune factor involved in delayed progression.
HIV-specific CD8 T cells elicited during PHI were capable
of inhibiting heterologous viral replication in vitro, and the
magnitude of this activity was related to Gag immunodomi-
nance. We next aimed to investigate whether HIV-specific CD8
T cells arising during acute/early HIV infection could suppress the
replication of lab-adapted X4 and R5 HIV strains and to which
extent, in comparison with chronic infection. It was also our aim
to establish a possible relationship between this viral inhibitory
activity (VIA) and the viral proteins targeted by the immune re-
sponse during the early stage of infection. To evaluate this, CD4
and CD8 cells were isolated from PBMCs obtained from seven
chronic subjects (including viremic controllers C03, C07, and
C08), seven EC, and 19 PHI subjects (10 from the PHI  350
group and 9 from the PHI  350 group). In PHI subjects, VIA was
evaluated at baseline samples as well as samples collected at 1 year
postinfection. CD4 T cells were isolated, activated, infected, and
then cultured either alone or in combination with autologous
CD8 T cells at a 1:1 ratio. Viral replication was assayed at day
seven postinfection by p24 ELISA. As previously described (16, 19,
20, 34, 35), CD8 T cells from EC mediated stronger VIA than
cells from chronics against both R5 (Fig. 4A) and X4 (data not
shown) viruses. Of note, EC equally inhibited both R5 and X4
viruses, indicating that these individuals had a broad VIA. It is
worth noting here that the use of heterologous lab-adapted viral
strains might lead to a VIA underestimation, and stronger differ-
ences among groups may be masked due to this reason (16). As for
the PHI group, most subjects (70%) demonstrated to have CD8
T cells capable of mediating VIA (median, 32%, in p24 reduction,
which corresponds to 1.5log10 VIA) against the R5 virus at base-






































































FIG 4 In vitro viral inhibitory activity (VIA) mediated by HIV-specific CD8 T cells. VIA is expressed as the log10 of the proportion of p24 antigen lost when
CD8 T cells were present in the culture, compared to CD4 cells alone. (A) Viral inhibitory activity found in chronic, EC, and PHI subjects, against lab-adapted
R5 HIV strains; (B) viral inhibitory activity in PHI individuals, reassorted into subjects with Gag immunodominance or Nef immunodominance according to
preferred (50% of total response) viral protein targeted by the immune response at baseline sample in the ELISPOT assay; (C) correlation between the
magnitude of Gag-specific response in PHI subjects at baseline sample and VIA; r and P values correspond to Spearman’s test; (D) PHI subjects with substantial
capacity to mediate VIA (25%) also showed higher CD4 T-cell set points. In panels A, B, and D, symbols show the values for each individual subject. Within
the chronic group (A), viremic controllers are denoted with black dots. Horizontal lines within boxes represent the median values. Intergroup and intragroup
(PHI baseline versus year) differences were analyzed using Mann-Whitney and Wilcoxon tests, respectively; *, P  0.05.
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VIA arise early during infection. Longitudinal analysis using
samples obtained at 12 months postinfection indicated that this
activity persists over time even beyond set point establishment
(Fig. 4A).
When the PHI group was split into the PHI  350 and PHI 
350 groups, no significant differences were observed in VIA either
at baseline or 12-month samples. Given our observation obtained
from the ELISPOT analysis, where Gag immunodominance dur-
ing PHI was associated with preservation of the CD4 T-cell
count over the first year postinfection, we decided to reassort PHI
individuals into Gag responders or Nef responders according to
preferred (50% of total response) viral protein target. This anal-
ysis revealed that CD8 cells from PHI individuals in which Gag-
specific cells dominated the early HIV-specific T-cell response had
a stronger capacity to mediate VIA against the R5 virus than Nef
responders, both at baseline (P 	 0.043) and at the 12-month
samples (P 	 0.011) (Fig. 4B). This result agrees with the fact that
EC consistently show the strongest VIA compared to other HIV
groups (in this and other studies) and concomitantly show a ro-
bust anti-Gag immunodominance of the HIV-specific cellular im-
mune response. In the same line, a statistically significant correla-
tion was found within the PHI group between VIA and the
magnitude of Gag-specific SFU (Spearman’s r 	 0.5885, P 	
0.0343; Fig. 4C). Overall, these results suggest that the ability of
HIV-specific CD8 T cells arising early during infection to sup-
press viral replication in autologous CD4 T cells might be re-
lated, among other factors, to the relative Gag immunodominance
out of the total HIV-specific CD8 T-cell response as well as the
absolute number of Gag-specific CD8 T cells. Also, it was ob-
served that EC and PHI Gag responders more frequently showed
VIA against both R5 and X4 viruses, while chronic and PHI Nef
responders recognized one, other, or no viruses, suggesting that
the former groups have broader activity (data not shown).
Given the consistent association of higher VIA with EC status
observed in this and other studies (16, 19, 20, 34, 35), we decided
to seek for any association of stronger VIA with clinical parame-
ters related to acute/early infection. No association was observed
between VIA magnitude and baseline viral load, viral set point, or
baseline CD4 T-cell count. However, it could be observed that
those subjects showing substantial capacity to mediate VIA
(25%) had higher CD4 T-cell set points (P 	 0.02, Fig. 4D),
suggesting that the association of Gag immunodominance with
delayed progression in terms of CD4 T-cell count preservation
described earlier in the manuscript (Fig. 3) would be related to a
higher capacity of Gag-specific cells to mediate VIA.
Low frequency of polyfunctional HIV-specific CD8 T cells
was detected during PHI; it slightly increased over time during
the first year postinfection but did not associate with viral or
CD4 T-cell set points. In order to further characterize HIV-
specific CD8 T cells arising early during infection, the function-
ality of these cells, in terms of their ability to degranulate (evi-
denced by CD107A/B mobilization) and to produce IFN-,
TNF-, and/or IL-2 upon peptide stimulation, was studied by
flow cytometry. For these assays, data obtained in the ELISPOT
screening was used as a starting point to define which peptide
pools were used as stimuli. So for each subject, only those peptide
pools for which positive responses were found by ELISPOT were
used as stimuli in the ICS assay. The gating strategy used is illus-
trated in Fig. 5A. The proportion of cells expressing each of these
functions alone or in combination was analyzed, not only in PHI
but also in chronic and EC subjects, in order to help distinguish
any association with disease progression.
As previously reported by our group (25), HIV-specific CD8
T cells expressing all the functions analyzed (either alone or in
combination) could be measured very early during infection.
Among PHI baseline samples, mean  SD percentages of HIV-
specific CD3 CD8 cells for each single function were 0.16 
0.28 for IFN-, 1.13  5.23 for TNF-, 0.06  0.14 for IL-2, and
0.21  0.4 for CD107. Figure 5B depicts the relative contribution
to the total specific CD8 response made by each function or
function combination. No particular function or function combi-
nation could be distinguished that differed substantially among
PHI, EC, or chronic subjects, except for bifunctional CD107A/B
IFN- CD8 T cells. All EC individuals had detectable bifunc-
tional CD107A/B IFN- CD8 T cells (mean, 30%  11% out
of the specific CD8 T cells), differing, in this sense, significantly
from chronic (13%  23%; P 	 0.007) and PHI individuals
(9%  14%; P 	 0.0004), indicating that this sub-subset of spe-
cific CD8 T cells could be relevant to virus control. Then, the
proportion of cells expressing one, two, or three functions was
studied among groups independently of any particular function.
As expected, the proportion of polyfunctional cells was greater in
EC than in chronic and PHI subjects (Fig. 5C). In particular, EC
had a significantly higher proportion of trifunctional cells (mean,
8.1%  7%) and significantly lower proportion of monofunc-
tional cells (mean, 46%  19%) than chronic subjects (mean,
2.7%  9% [P 	 0.013] and 68%  27% [P 	 0.033], respec-
tively). As mentioned above, bifunctional and trifunctional cells
could be measured very early in PHI, together accounting for
25.5% of the HIV-specific CD8 pool in these subjects. Moreover,
the proportion of these cells seemed to slightly increase over time
to the 12-month sample (32.3%), although the difference between
the baseline and year samples did not differ significantly. Within
the PHI group, no significant differences were observed in any
particular function or function combination when individuals
were segregated into PHI  350 and PHI  350 groups. Similarly,
no difference was observed between both groups in the propor-
tion of mono-, bi-, or trifunctional cells. Also, no significant cor-
relation was observed for any function, combination, or propor-
tion either with baseline or set point VL or CD4 T-cell count
(data not shown).
It was then hypothesized that the stronger CD8 T-cell VIA
found in PHI subjects in whom Gag dominated the cellular
immune response, as well as the slower progression observed
within this subgroup, could be related to higher polyfunction-
ality of Gag-specific cells. Consequently, the proportion of
Gag- and Nef-specific CD8 T cells expressing one, two, or
three functions was compared within the PHI group at baseline
and 12-month samples (Fig. 5D). No differences were observed
for both antigens, indicating that polyfunctionality was not
related to specificity. Moreover, both Gag- and Nef-specific
responses showed a nonstatistically significant increase in
polyfunctionality over time.
Overall, these results suggest that although a higher propor-
tion of polyfunctional CD8 T cells is associated to EC status
and even when these cells could be measured very early in HIV
infection, they would not be associated with better or worse
resolution of acute phase. Also, the benefits of Gag-specific
cells would not be related to polyfunctionality in the terms
analyzed here.
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FIG 5 (A) Gating strategy used for the identification of degranulating and cytokine-secreting HIV-specific T cells. Illustration data were derived from one
representative subject, stimulated with an HIV peptide pool. Initial gating was performed on a plot of forward scatter area (FSC-A) versus height (FSC-H) to
remove doublets. Then, gating was performed on small lymphocytes in a plot of forward scatter (FSC) versus side scatter (SSC). Dead cells were then excluded
Turk et al.
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A higher proportion of HIV-specific CD8 T cells able to de-
granulate and secrete IFN- was associated with improved ca-
pacity to suppress viral replication during PHI. As mentioned
before, out of the multiple CD8 T-cell effector functions studied
by flow cytometry, the combined expression of CD107A/B and
IFN- was significantly associated with EC status (Fig. 5B). Given
this, it was reasoned that the particular combination of these two
functions (instead of polyfunctionality as a whole) would be asso-
ciated with improved resolution of acute infection. Thus, associ-
ations among percentages of specific CD107A/B IFN- CD8
T cells and virological and immunological parameters (all corre-
sponding to baseline samples) were analyzed. It was found that,
within PHI subjects, those showing substantial CD8 T-cell VIA
(25%) had higher numbers of CD107A/B IFN- CD8 T
cells than those having weak (25%) VIA (P 	 0.025). Even
more, the percentage of CD107A/B IFN- CD8 T cells in the
PHI VIA  25% group was comparable to that of EC (Fig. 6A and
B). Moreover, a significant correlation between the percentage of
specific CD107A/B IFN- CD8 T cells and the CD8 T-cell
VIA was found for PHI subjects (Spearman’s r 	 0.6383, P 	 0.01;
Fig. 6C).
These observations indicate that the capacity to degranulate
and express IFN- might play a relevant role in the ability of spe-
cific cells to mediate VIA (i.e., to suppress viral replication in
on the bases of LIVE/DEAD fluorescence. Subsequently, CD3CD8 cells were gated in a CD3-versus-CD8 dot plot. Following identification of these cells, a gate
was made for each function studied: degranulation (evidenced as CD107A/B surface expression) and production of IFN-, IL-2, and TNF-. (B) Relative
contribution to the total specific CD8 response made by each function or function combination in PHI (baseline sample), chronic, and EC subjects. Symbols
represent the percentage out of the total specific CD8 T cells expressing the particular combination of functions indicated on the axis, for each subject.
Responses shown correspond to background-subtracted results using the CD28/49d control. Values corresponding to bi- and monofunctional cells were
corrected by subtracting the values corresponding to triple-positive events and double- and triple-positive events, respectively. Horizontal lines within boxes
represent the median values. (C) Summary of functional profile in chronic, EC, and PHI subjects (baseline and year samples in the case of the PHI group). The
distinct cellular subsets shown in panel B were grouped by number of functions, so each section of the bars represent, the mean proportion of specific CD8 T
cells expressing one (white), two (gray), or three (black) functions, independently of any particular function, matching the color code used in panel B. (D) Results
corresponding to PHI subjects, using either Gag or Nef peptide pools as stimuli. *, P  0.05; **, P  0.01; ***, P  0.005.






















































FIG 6 Association between the CD8 T-cell capacity to suppress HIV replication in vitro and the frequency of HIV-specific T cells able to degranulate and secrete
IFN- upon stimulation. (A) Frequency of HIV-specific CD107A/B IFN- CD8 T cells in EC, chronic, and PHI subjects (segregated according to CD8
T-cell VIA magnitude). *, P  0.05 Mann-Whitney test. (B) Representative IFN- versus CD107A/B dot plots (gated on CD3CD8 events) obtained for
subjects of each group. (C) Correlation between the frequency of HIV-specific CD107A/B IFN- CD8 T cells and VIA in PHI subjects at baseline sample. r
and P values correspond to Spearman’s test.
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vitro), which in turn associated both with the preservation of the
CD4 T-cell subset during acute/early infection and the status of
EC. On these bases, the subpopulation of specific CD107A/B
CD8 T cells was subjected to a deeper analysis. This analysis
revealed that, out of the total CD107A/B HIV-specific CD8
cells, most of them coexpressed IFN- and/or IL-2 in the EC co-
hort, i.e., most degranulating HIV-specific CD8 T cells from EC
were bi- or trifunctional. Of note, all EC had measurable HIV-
specific CD107A/B IFN- CD8 T cells, and around 60% of
subjects had measurable HIV-specific CD107A/B IL-2 CD8 T
cells. On the contrary, only a minor portion of chronic and PHI
subjects exhibited polyfunctional HIV-specific CD107A/B
CD8 T cells. When a similar analysis was performed but consid-
ering response specificity, it could be observed that Gag-specific
CD107A/B CD8 T cells showed higher levels of polyfunction-
ality than Nef-specific cells in chronics, even comparable to Gag-
specific cells from EC. However, no difference was observed
between Nef- and Gag-specific CD8 T cells in terms of polyfunc-
tionality associated to degranulation capacity in the PHI group,
either at baseline or 12-month samples (not shown).
Finally, the relative mean fluorescence intensity (rMFI) of
IFN- and CD107A/B was studied in specific CD8 T cells as an
indicator of cell function strength (Fig. 7). IFN- rMFI analysis
(Fig. 7A) produced results that paralleled those obtained after the
examination of spot sizes in the ELISPOT assays. CEF-specific
cells showed 1.7-fold-higher (1.7
) IFN- rMFI than HIV-spe-
cific cells in the chronic (P 	 0.03) and EC (P  0.05) groups but
not in the PHI group. As for CD107 expression, no difference was
observed among groups regarding CEF-specific cells (Fig. 7B).
When CD107A/B rMFI was compared intragroup, it was found
that Gag-specific cells showed higher CD107A/B rMFI than Nef-
specific cells both in chronic (1.7
, P  0.05) and PHI subjects
(1.4
, P 	 0.033). Even more, CD107A/B rMFI for Gag-specific
cells was comparable to that of CEF-specific cells in all three
groups of subjects analyzed. When the same analysis was per-
formed but gated on double-positive CD107A/B IFN- CD8
T cells, it could be observed that rMFI was higher for each func-
tion, as already reported for polyfunctional cells (36), and the
same trends shown in Fig. 7 were maintained. Even more, the
differences on CD107A/B expression between Nef- versus Gag-
specific cells became more pronounced. However, this observa-
tion was derived from only a minor subset of patients and a small
number of events (especially for chronic and PHI subjects) in
order to draw definite statements.
In summary, EC showed a higher number of degranulating
HIV-specific CD8 cells than chronic and PHI subjects. Even
more, in these subjects, this activity was more frequently accom-
panied by the capacity to secrete cytokines (IFN- and/or IL-2),
while in the chronic and PHI groups, these cells were mostly
monofunctional. Within PHI, a direct correlation between the
percentage of HIV-specific CD107A/B IFN- CD8 T cells and
the magnitude of CD8 T-cell VIA was found. Finally, Gag spec-
ificity was associated with a stronger ability to degranulate (evi-
denced by higher CD107 rMFI), which seems consistent with
these cells having a stronger capacity to mediate viral inhibition.
Plasma levels of MIP-1 and IL-2 are associated with Gag
immunodominance. Cytokines play a key role in many infectious
diseases, both shaping the immune response mounted against
pathogens and contributing to pathogenesis. Several reports have
established that plasma cytokine levels measured during acute
HIV infection may predict subsequent disease progression (37–
39). In this scenario, we sought to analyze the relationship be-
tween plasma cytokine levels during acute/early HIV infection
and the Gag or Nef immunodominance hierarchy obtained also at
PHI baseline samples. This was performed with the aim of deter-
mining if there existed an association between both soluble and
cellular immune signatures associated with protection from dis-
ease progression and following the hypothesis that if two immune
parameters are truly determinants of protective immunity, then a
direct association between them should be observed. It was found
that the percentage of Gag-specific cells out of the total HIV-spe-
cific cells (baseline Gag%) significantly correlated in a direct fash-
ion with plasma levels of MIP-1 and IL-2, among PHI subjects at
baseline samples (Fig. 8A and B). Although the correlation be-
tween plasma MIP-1 and baseline Gag% was not significant after
the adjusted analysis, the clear trend indicating a direct association
between both parameters is still worth noting. Conversely, the
proportion of Nef-specific cells inversely correlated with plasma
MIP-1 (Fig. 8C). These findings are of particular importance,
since these molecules are produced by CD8 T cells upon stimu-
lation and the percentage of cells expressing IL-2 and MIP-1
either alone or in combination with other functions were previ-






































FIG 7 Relative mean fluorescence intensity (rMFI) of IFN- (A) and CD107A/B (B) in Nef-, Gag-, and CEF-specific CD8 T cells, calculated as the ratio between
MFI corresponding to specific versus total CD8 T cells for a given channel, in chronic, EC, and PHI subjects. Symbols show the values for each individual subject.
Horizontal lines within boxes represent the median values. *, P  0.05; ND, not determined.
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ously associated with virus control (6, 17, 18, 20, 40). Moreover,
soluble MIP-1 was also reported to mediate viral inhibition in
vitro (41). The fact that there exists an association between impor-
tant soluble antiviral mediators such as IL-2 and MIP-1 and Gag
immunodominance is in line with the evidence indicating that
early relative Gag immunodominance is somehow related to the
generation of a robust, efficient, and multifaceted antiviral im-
mune response, thus reinforcing the notion that it is one key de-
terminant of protective immunity contributing to slower disease
progression.
DISCUSSION
Data accumulated over the past years, based on both experimental
infections in nonhuman primate models and natural infections in
humans, have established that the HIV-specific CD8 T-cell re-
sponse plays a critical role on viral control (reviewed in references
2 and 3). This is particularly evident during acute infection, where
the up-slope of arising HIV-specific CD8 T cells is temporarily
associated with the decline in the initial peak viremia (4). For this
reason, efforts have been made to understand which particular
functions and/or phenotypes, out of the global CD8 T-cell sub-
set, best correlate with control of viral replication (3). Moreover, it
is thought that this information will be instrumental for develop-
ing and enhancing immunization strategies as well as for defining
immune correlates of protection, which are currently lacking, in
order to evaluate the performance of vaccine candidates. In line
with this, cohort studies addressing the association of particular
features of CD8 T-cell responses arising during acute/early HIV
infection with potential markers associated with disease progres-
sion are fundamental. To date, most of these studies come from
cohorts settled in Europe, North America, or Africa, and scarce
information exists on this issue from other settings, such as South
America. Here, we report the study of multiple functional aspects
of the HIV-specific CD8 T-cell compartment arising early after
infection in a subset of subjects from a well-characterized cohort
of Argentinean seroconverters, in comparison to that found in,
also local, viremic chronics and elite controllers. Epidemiological,
clinical, immunological, and virological characteristics of the pa-
tients enrolled in the cohort are described elsewhere (26). Aiming
at delineating CD8 T-cell features that best associate with disease
progression in our population, it was found that (i) there exist
early differences regarding the immunodominant viral targets of
the specific T-cell response between subjects with different rates of
progression to disease (in terms of CD4 T cell loss) during the
first year of infection (Fig. 2 and 3), (ii) polyfunctional HIV-spe-
cific CD8 T cells could be detected during PHI but their fre-
quency was not associated with virus control or protection from
progression (Fig. 5), (iii) CD8 T cells capable of mediating viral
inhibitory activity (VIA) in vitro could also be detected during
PHI (Fig. 4), and (iv) the improved capacity to mediate VIA dur-
ing PHI was associated with a higher CD4 T-cell set point and
was related to Gag immunodominance and a higher proportion of
HIV-specific CD8 T cells able to degranulate and secrete IFN-
(Fig. 4 and 6). The main contribution of this study relies on the
correlation between the HIV-specific CD8 T-cell functional
properties during acute/early infection and the clinical outcomes
during the first year postinfection. On the other hand, to our
knowledge, this is the first report to perform an immunological
characterization of the T-cell responses in a cohort of acute/early
HIV-infected subjects from South America.
Clear differences in the viral proteins that are targeted by the
HIV-specific cellular response have been described between the
acute/early and chronic phases of infection: while Nef-specific
cells dominate the early antiviral response (42), this response af-
terward broadens toward epitopes contained within other viral
proteins, such as Gag, Env, and Vpr (11–15). Many of these studies
have also established that Gag-specific CD8 T-cell responses are
associated with low viremia in chronic infection. Other reports
indicate that Gag is the immunodominant target in elite control-
lers (43), both in blood and mucosal tissues (44), providing fur-
ther support to the important role of Gag-specific cells in restrict-
ing viral replication. Possible mechanisms to explain this better
ability to control viral replication include ability to kill very re-
cently infected cells (even before viral genome integration to host
genome) (45, 46), Gag fitness constraints to escape immune pres-
sure (47, 48), and higher capacity to mediate antiviral activity,
which will be discussed in the following paragraphs. In line with
these findings, we found that Gag-specific cells (particularly p24-
specific cells) dominated the HIV-specific response in EC, both in
terms of magnitude and hierarchy (Fig. 2A and B). Also, Gag im-
munodominance was observed in a subgroup of chronically in-
fected subjects referred to as “viremic controllers.” On the con-
trary, Nef-specific cells dominated the response in PHI subjects.
However, when this group was split into PHI  350 and PHI 



























































FIG 8 Correlation between anti-Gag and anti-Nef cellular immune response immunodominance hierarchy and plasma cytokine/chemokine levels in PHI
subjects at baseline samples. Significant correlations were found between the relative immunodominance of Gag (A and B) and Nef (C) with plasma IL-2 (A) and
MIP-1 (B and C) levels. r and P values correspond to Spearman’s test. *, P values adjusted by the Benjamini and Hochberg method for false discovery rate (FDR)
procedure.
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progression (PHI  350), Nef clearly dominated the anti-HIV
response (Fig. 2A to C). More importantly, significant correla-
tions between baseline Gag immunodominance and both baseline
and set point CD4 T-cell counts were observed in the PHI group
(Fig. 3). In line with this result, other authors described a direct
correlation between the magnitude of the anti-Nef CD8 T-cell
response and viral load in a cohort of HIV subtype C acutely
infected subjects (49). Overall, these results argue in favor of that
an earlier and higher contribution of Gag-specific cells to the hi-
erarchy of the total anti-HIV response at very early time points
postinfection contributes to a slower disease progression.
The ability of CD8 T cells to kill virus-infected cells may rely
in their specificity, phenotype, and/or functionality and could
even be mediated by distinct mechanisms (mediated by soluble
factors or cell-to-cell contact). The evaluation of the ex vivo virus
inhibitory activity (VIA) results in an overall measurement of the
total CD8 T-cell antiviral potency. Previous reports have used
this assay to evaluate VIA mediated by CD8 T cells obtained
from elite controllers, treated and untreated chronically infected
individuals (16, 19, 20, 34, 35), as well as human and simian vac-
cinees (20, 50). In these studies, it was demonstrated that VIA
correlates with the magnitude of the Gag-specific CD8 T-cell
response (16, 35), that the expression of “protective” HLA-I alleles
is not a required condition (20, 35), and that it is associated with
higher frequencies of degranulating (as measured by CD107A/B
expression) specific CD8 T cells, usually accompanied by other
functions, such as secretion of IFN- and MIP-1 (20, 35, 50). In
agreement with this background, we found that CD8 T cells
from EC mediated stronger and broader VIA than those cells from
untreated chronic subjects. Additionally, we also demonstrate in
this work that VIA can be measured very early after infection in
most acutely infected subjects (although to a lower magnitude
than EC) and that this activity persists over time (Fig. 4). To our
knowledge, there exists only one very recent report studying VIA
in acute HIV infection (41). In that work, Freel and collaborators
also demonstrate (i) that VIA magnitude correlates with the per-
centage of HIV-specific CD8 T cells expressing CD107A, MIP-
1, and IFN- and with the secretion of MIP-1, MIP-1, IFN-,
IP-10, and IL-1 after cell stimulation with peptide antigens and
(ii) that early escape from CD8 T-cell-mediated VIA occurs dur-
ing PHI. In our work, further insights are provided into the role of
CD8 T-cell-mediated VIA during PHI. Aiming at delineating the
specificity and functionality of VIA-mediating cells during PHI, it
could be established that CD8 cells from PHI individuals in
whom Gag-specific cells dominated the early HIV-specific T-cell
response had stronger capacity to mediate VIA than Nef respond-
ers, and a statistically significant direct correlation was found
within the PHI group between VIA and the magnitude of Gag-
specific cellular immune response (Fig. 4). This is in line with
results obtained for EC and chronic subjects with broad anti-Gag
responses (16, 35) and could provide an additional mechanistic
explanation for the pivotal role of Gag-specific cells in delayed
disease progression. Although Freel et al. (41) found that Nef-
specific cells could mediate VIA to the same extent as Gag-specific
cells in acutely infected subjects, no association between these ac-
tivities and clinical parameters was studied by these authors, as it is
the case of the present work. Also, it is important to denote that
both studies differ in definition of the specificity of VIA-mediating
cells, which may account for the different results obtained. Re-
garding the functionality of VIA-mediating cells, we found that,
within PHI subjects, those showing substantial CD8 T-cell VIA
(25%) had a higher frequency of CD107A/B IFN- CD8 T
cells (even comparable to EC) than those having weaker VIA.
Moreover, a significant correlation between the percentage of spe-
cific CD107A/B IFN- CD8 T cells and the CD8 T-cell VIA
was found for PHI subjects (Fig. 6). In regard to the expression of
CD107A/B, this result is in line with previous data obtained for
EC, chronic, acute/early infected subjects and simian vaccinees
(35, 41, 50). However, in our study, the simultaneous coexpres-
sion of both markers (CD107A/B and IFN-) is necessary to
maintain the association. Other groups reported that MIP-1 se-
cretion is also associated with VIA both in chronic and acute in-
fection (20, 41). Because of technical constrains, we could not
include the evaluation of this cytokine in our multicolor flow cy-
tometry assay. However, it is presumable that a similar association
would have been found due to the high contribution of MIP-1 to
the total response during acute infection and its high rate of coex-
pression with CD107A/B and IFN- (6, 25). What we did ob-
served was a nonsignificant yet border correlation between plasma
MIP-1 (see further discussion below) and the proportion of bi-
functional degranulating cells, i.e., the proportion of CD107
IFN- plus CD107 IL-2 HIV-specific CD8 T cells out of the
total CD107 HIV-specific CD8 T cells (Spearman’s r 	 0.4368,
P 	 0.0699; data not shown), suggesting an association between
VIA, degranulation, and expression of MIP-1. Finally, as it has
been documented for chronic infection (35), no association was
found between VIA magnitude and viral load. However, we could
observe an association between VIA and the CD4 T-cell set point
(Fig. 4D). This result, together with the higher VIA observed in EC
(in our and other studies mentioned above) and an observation
made in vaccinated rhesus monkeys where strong VIA was related
to enhanced virus control in breakthrough infections (50), clearly
indicates that CD8 T-cell-mediated VIA is a desirable feature to
be elicited by prophylactic or therapeutic interventions aimed at
delaying disease progression.
Early reports comparing the capacity of CD8 T cells to de-
granulate and secrete multiple soluble mediators upon stimula-
tion, between individuals with progressive versus long-term non-
progressive HIV infection, have suggested that CD8 T-cell
polyfunctionality would be a functional correlate of virus control
(17, 18). However, these studies also raised the question of
whether polyfunctionality was not the cause but the consequence
of virus control. Results presented here argued in favor of the
latter hypothesis: in our PHI cohort, polyfunctional HIV-specific
CD8 T cells could be measured very early during infection (in
consonance with our previous observation [25]), and the propor-
tion of these cells seemed to slightly increase over time to the
12-month sample (Fig. 5), as also reported by Ferrari et al. (6).
Although significant differences in the proportion of polyfunc-
tional cells were observed in EC versus viremic chronic subjects
(as expected, based on previous reports [17, 51]), no significant
differences were observed when PHI individuals were segregated
as rapid (PHI  350) or regular (PHI  350) progressors. More-
over, polyfunctional profiles were similar in PHI individuals with
different immunodominant targets, indicating that polyfunction-
ality was not related to specificity (Fig. 5). These findings shed
more light into the notion that, instead of being a marker of anti-
viral function, T-cell polyfunctionality would be directly affected
by viral persistence. In other words, lack of T-cell polyfunctional-
ity would be the consequence of constant antigen stimulation dur-
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ing viremic chronic infection, which ultimately may lead to cell
exhaustion and functional impairment, as postulated previously
(6, 21). In this sense, CD8 T-cell phenotypic characterization in
terms of exhaustion and memory markers in our cohort is being
currently performed. On the other hand, the demonstration that,
out of the many CD8 T-cell function combinations studied, only
the frequency of specific bifunctional CD107A/B IFN- CD8
T cells correlated with the magnitude of CD8 T-cell VIA (Fig. 6)
would indicate that not all the functions exerted by a polyfunc-
tional cell would be equally relevant in mediating antiviral T-cell
effector functions.
T-cell functional outcomes upon antigen engagement depend
on the strength of the stimulus, which can be directly affected by
the level of antigen sensitivity or cell avidity (52, 53). These pa-
rameters, in turn, can be indirectly inferred by computing the
mean spot size in the IFN- ELISPOT assay (33) or the rMFI of a
given function evaluated by flow cytometry (52). Here, we found
that the analysis of IFN- mean spot size and IFN- rMFI gave
comparable results, together indicating that HIV-specific cells
showed less quality in all groups analyzed compared to CEF-spe-
cific cells (in EC the difference was not significant) (Fig. 2F and 7).
CEF-specific cells were analyzed for comparison since they repre-
sent cells that target pathogens that were either cleared (influenza)
or controlled (CMV and Epstein-Bar viruses), thus their analysis
could provide putative signatures associated with virus control.
This result suggests again that constant HIV antigen stimulation
may be driving cell exhaustion. Moreover, and regardless of the
specificity, cells from PHI subjects showed the lowest quality
among all the groups analyzed, suggesting that, during acute/early
HIV infection, there exists an overall deterioration of the CD8
T-cell compartment. In regard to CD107A/B mobilization, it was
found that rMFI for Gag-specific cells was higher than for Nef-
specific cells and comparable to that of CEF-specific cells in all
three groups of subjects analyzed (Fig. 7). A relation among the
magnitude of CD107A/B mobilization (evaluated by flow cytom-
etry as in this work), antigen sensitivity, and antiviral activity has
previously been established in another setting (52), supporting
our association between the stronger ability of Gag-specific cells to
degranulate and their stronger capacity to mediate viral inhibi-
tion.
A large amount of data indicate that the expression of certain
HLA-I molecules is related to HIV control. Part of the evidence
came from cohort studies where some alleles were overrepre-
sented in EC and long-term nonprogressors (7, 8), while other
studies provided insights into functional performance of the “pro-
tective alleles” regarding specificity, proliferation, polyfunctional-
ity, antigen presentation, immune pressure, among other factors
(8, 54–61). However, it has also been demonstrated that these
protective alleles perform qualitatively different in controllers
compared to progressors (60), indicating that a combination of
T-cell function and phenotypes should coexist in order to achieve
virus control. Conversely, some individuals reach EC status in the
absence of protective alleles (as it can be observed in our cohort),
indicating that they are not a requirement for virus control. For
instance, CD8 T-cell VIA can be observed both in the presence
and absence of protective HLA-I alleles (20, 35). Although in this
work a simultaneous evaluation of multiple CD8 T-cell func-
tions (in different terms such as magnitude, breadth, immuno-
dominant targets, polyfunctionality, and VIA) was performed in
HLA-typed individuals with known disease status, both the cohort
size and the heterogeneity of alleles and responses preclude us
from unequivocally establishing the relationship between CD8
T-cell function and phenotype and disease outcome. Further
studies aimed at developing a model involving these three param-
eters will be needed.
The cytokine network elicited after HIV/simian immunodefi-
ciency virus (SIV) infection has been studied in order to shed light
on the early pathogenic events of the infection and to understand
how these events trigger the future course of the disease. More-
over, the level of different plasma cytokines and/or chemokines
during acute infection has been proposed as a potential biomarker
to predict the rate of disease progression (37–39, 62). However, to
our knowledge, no report has established so far the relationship
between plasma molecules and the HIV-specific cellular immune
response. Here, a correlation between the relative immunodomi-
nance of the anti-Gag response and the levels of IL-2 and MIP-1
was found (Fig. 8). As mentioned before, these molecules are pro-
duced by CD8 T cells upon stimulation, and the percentage of
cells expressing IL-2 and MIP-1 either alone or in combination
with other functions were previously associated with virus control
(4, 11, 14, 43, 49). IL-2 is an important molecule for T-cell homeo-
stasis and immune system activation (63). Although different lev-
els of plasma IL-2 during PHI infection have not been previously
associated with HIV/AIDS disease outcome, decreased levels of
other molecules also involved in T-cell homeostasis and T-cell
phenotype determination, such as IL-15 and IL-12, respectively,
have been associated with progressive infection in a cohort of
chronically infected African-American women (38). On the other
hand, it was determined that MIP-1-producing CD8 T cells
represent an elevated proportion within the HIV-specific CD8
T-cell response during acute infection and that they exert consid-
erable immune pressure over viral replication (6). At the func-
tional level, it was suggested that the production of MIP-1 is
rapidly elicited upon stimulation on the specific cells (52), which
may account for an enhanced activity of the MIP-1-producing
CD8 T cells over cells exerting other functions. Moreover, other
authors have found an association between MIP-1 plasma levels
and lower VL and higher CD4 T-cell counts during chronic in-
fection (38). Taken together, all this evidence provides a rationale
for the association between the protective role of immunodomi-
nant Gag-specific cellular response and plasma levels of IL-2 and
MIP-1. As already mentioned, and although further investiga-
tions will be needed to determine the nature of this relationship,
these results are in line with the evidence indicating that early
relative Gag immunodominance is somehow related to the gener-
ation of an effective antiviral immune response leading to slower
disease progression.
In summary, multiple aspects of the HIV-specific CD8 T-cell
subset (specificity, ex vivo viral inhibitory capacity, and polyfunc-
tionality) arising early after infection were characterized in a co-
hort of acute/early infected subjects, in comparison with that
found in viremic chronics and elite controllers. Importantly, the
association of these functions with disease progression was stud-
ied. In the first place, it was found that specificity of cells arising
early after the transmission event is critical for immune control:
early relative immunodominance of Gag-specific cells was associ-
ated with delayed disease progression, in terms of CD4 T-cell
count preservation, during the first year postinfection, in conso-
nance with Gag immunodominance in EC and viremic control-
lers. Further insights into the functionality of CD8 T cells from
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enrolled subjects allowed us to establish that the advantage of
Gag-specific CD8 T cells would rely on their ability to mediate
both lysis of infected cells (evidenced by higher capacity to de-
granulate and to mediate viral inhibition activity in vitro) and
soluble inhibition of viral replication by the simultaneous secre-
tion of IFN-. Also, higher relative contribution of anti-Gag-spe-
cific cells to the total anti-HIV cellular immune response corre-
lated with plasma levels of IL-2 and MIP-1, molecules that
further contribute to viral inhibition.
The identification of phenotypic and functional properties of
the CD8 T-cell subsets associated with viral control is urgently
needed to aid in the design and performance evaluation of an
effective HIV vaccine. In this scenario, data presented in the man-
uscript underscore the importance of considering both cell spec-
ificity and quality, in terms of both cytotoxic and noncytotoxic
mechanisms, to boost preventive and therapeutic anti-HIV im-
mune-based strategies.
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